-

04:40:09 AM

BTAI Stock News

BTAI - BioXcel Therapeutics Inc

06/01/23 7:00 AM

Nasdaq : BTAI

conferenceslow float

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel

RHEA-AI

neutral

05/25/23 7:00 AM

Nasdaq : BTAI

clinical triallow float

BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™ Greater than 50% PEC response rate attained; proportionally consistent with dose response when compared to rates seen in SERENITY I and II BXCL501 was well tolerated and demonstrated favorable safety

RHEA-AI

neutral

05/16/23 7:00 AM

Nasdaq : BTAI

clinical triallow float

BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program

BXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically Planning Phase 2 human proof-of-concept study to evaluate BXCL501 as a potential adjunctive treatment in MDD Data further supportive of ongoing clinical programs evaluating BXCL501 for potential

RHEA-AI

neutral

05/08/23 7:00 AM

Nasdaq : BTAI

earningslow float

BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights

IGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote Top-line data from pivotal SERENITY III Phase 3 trial (Part 1) for BXCL501 in bipolar or

RHEA-AI

negative

05/02/23 7:00 AM

Nasdaq : BTAI

conferenceslow float

BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel

RHEA-AI

neutral

04/24/23 7:00 AM

Nasdaq : BTAI

conferencesearningslow float

BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter

RHEA-AI

neutral

03/14/23 4:15 PM

Nasdaq : BTAI

IPOofferinglow float

OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

OnkosXcel Therapeutics, LLC (“OnkosXcel”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering

RHEA-AI

neutral

03/09/23 7:00 AM

Nasdaq : BTAI

earningslow float

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

IGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team Multiple pivotal data readouts for BXCL501 expected in Q2 2023 in disease areas with 139 million agitation episodes, 1- 3 * including

RHEA-AI

neutral

02/23/23 7:00 AM

Nasdaq : BTAI

conferencesearningslow float

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter

RHEA-AI

neutral

02/21/23 7:00 AM

Nasdaq : BTAI

low float

BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today

BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 10 Next

BTAI Data

IndustryPharmaceutical Preparation Manufacturing
Websitebioxceltherapeutics.com
CeoVimal Mehta
Security nameBioXcel Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees183
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address555 Long Wharf Dr
StateConnecticut
CityNew Haven
Zip06511-6107
CountryUS
Phone12036438060

About BioXcel Therapeutics Inc

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.